Asceltis receives China IND nod for clinical trials of ASC42 for CHB
Category: #health  By Pankaj Singh  Date: 2021-06-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Asceltis receives China IND nod for clinical trials of ASC42 for CHB

Elevating cases of chronic hepatitis B (CHB) has now impelled Asceltis Pharma Inc., a data driven biotech firm in China, to experiment towards developing drugs that can, to some extent, reduce the impact of CHB in the human body.

In light of this, the company recently announced that China National Medical Products Administration produced an Investigational New Drug (IND) approval for its drug candidate- ASC42 to undertake clinical trials for the CHB indication.

For the record, ASC42 is an in-house developed, potent, selective FXR agonist. It is an oral formulation advanced with in-house patent technology, which is considered to be stable at room temperature.

It has been reported that both in-vitro primary human hepatocyte cells and in-vivo HBV/AAV mouse studies, earlier, presented that the ASC42 drug candidate significantly repressed serum hepatitis B antigen and HBV pregenomic RNA. This implies that ASC42 boasts of therapeutic potential to cure CHB.

Reports suggest that as an FXR agonist, ASC42 has exceptional operation against HBV as it prevents the transcription of HBV cccDNA into HBV RNA, in turn repressing the translation of HBV RNA into HBsAg.

Apparently, the ASC42 drug is also likely to reduce HBV cccDNA stability.

It would be crucial to mention that ASC42 is the second investigational new drug of the company for HBV functional cure. Another investigational new drug for HBV cure is ASC22, which is currently in Phase IIb analysis. The study showcased preliminary efficacy and good safety in HBsAg reduction in Phase IIa evaluation.

Commenting on the latest accomplishment, Founder, Chairman and CEO of Asceltis, Dr. Jinzi J. stated that the firm is quite thrilled about ASC42 IND nod for CHB. Dr. Jinzi addressed this achievement as a key milestone for its CHB functional cure pipeline. He further added that the potential synergy between ASC22 and ASC42 is promising for the company’s effort on CHB functional cure.

Source Credit: https://www.prnewswire.com/news-releases/ascletis-received-china-ind-approval-of-its-fxr-agonist-asc42-for-chronic-hepatitis-b-indication-301306416.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Covid-19 could end in Europe after the Omicron wave, says WHO
Covid-19 could end in Europe after the Omicron wave, says WHO
By Pankaj Singh

The new Omicron variant has shifted the pandemic into a new phase and could end in Europe, claims WHO Europe Director Hans Kluge recently. Mr. Kluge told sources that it could be possible that the region is heading towards a pandemic endgame, adding...

Scotland scientists develop AI-based test using X-rays to detect COVID-19
Scotland scientists develop AI-based test using X-rays to detect COVID-19
By Pankaj Singh

Scientists in Scotland have reportedly created an AI (artificial intelligence) based test that detects COVID-19,accurately, using X-rays in just a few minutes. The testing platform, developed at the University of the West of Scotland (UWS), can detec...

STG announces launch of Trellix; aims for technological innovation
STG announces launch of Trellix; aims for technological innovation
By Pankaj Singh

Symphony Technology Group (STG), an American private equity firm, has recently announced the launch of Trellix. This innovative business will be bringing prolonged XDR (detection and response) to firms while focusing on fastening technology innovatio...